Sai Life Sciences (SAILIFE) investor relations material

Executive summary

• Q1 FY27 revenue grew 12% year-over-year to ₹554 crore, driven by strong CRO (up 24%-26% YoY) and CDMO (up 6% YoY) performance, with robust momentum in integrated and FTE-based pharma partnerships.

• Strategic focus is on evolving from a small molecule CRDMO to a technology-led multimodality partner, expanding capabilities in peptides, conjugates, and formulations.

• Repeat business remains high, with over 90% of revenue from returning customers and increasing strategic engagements with large pharma clients.

• Maintains a healthy balance sheet and disciplined capital allocation, supporting long-term growth strategy.

• Sustainability recognized with EcoVadis Platinum rating, placing the company in the top 1% globally.

Financial highlights

• Q1 FY27 total revenue: ₹554 crore (₹5,542.85 million), up 12% YoY from ₹496 crore (₹4,964.19 million); PAT: ₹73 crore (₹732.85 million), up 22% YoY.

• CRO contributed 40% of revenue, growing 24%-26% YoY; CDMO contributed 60%, growing 6% YoY.

• EBITDA margin improved to 27% from 25% in Q1FY26; PAT margin at 13%.

• Capex incurred: ₹263 crore in Q1FY27; capacity utilization at 65%.

• Supported five FDA-approved molecules in calendar 2025 and 17 launches over five years.

Outlook and guidance

• H2 FY27 expected to be stronger than H1 due to new capacity coming online.

• Mid-term revenue growth guidance maintained at 15%-20% CAGR, with EBITDA margin guidance of 28%-30%.

• Over 90% pipeline visibility on FY27 targets, with continued focus on integrated service delivery and expanding large pharma collaborations.

• CapEx guidance for FY27 is ₹1,100–1,300 crore; no guidance yet for FY28.

• Capacity expansion on track to reach 1,150 KL by FY27.